Found 41 articles for: "Dermatitis"
A Consensus on Staphylococcus aureus Exacerbated Atopic Dermatitis and the Need for a Novel Treatment
October 2024 | Volume 23 | Issue 10 | Original Article | 825 | Copyright © October 2024
The skin microbiome is essential for skin barrier function because it inhibits pathogen colonization, and decreased microbiome diversity correlates with increased Staphylococcus aureus (S. aureus...
Read MoreAssessing Patient Preferences for Atopic Dermatitis Treatment: A Review Article of Discrete Choice Experiments
October 2024 | Volume 23 | Issue 10 | Original Article | 847 | Copyright © October 2024
Atopic dermatitis (AD) is one of the most prevalent inflammatory skin conditions, characterized by recurrent eczema with varying degrees of erythema, pruritus, xerosis, and pain. Although there a...
Read MoreA Brief Report of 13 Cases of Poppers Dermatitis
October 2024 | Volume 23 | Issue 10 | Features | 899 | Copyright © October 2024
Topical Treatment of Atopic Dermatitis: An Adherence-Based Appraisal of the AAD Guidelines
October 2024 | Volume 23 | Issue 10 | Features | 897 | Copyright © October 2024
Dermatologic Procedures for the Treatment of Seborrheic Dermatitis
October 2024 | Volume 23 | Issue 10 | Original Article | 819 | Copyright © October 2024
Background: This paper examines alternative procedural interventions for Seborrheic Dermatitis (SD), aiming to offer clinicians more treatment options and encourage further resea...
Read MoreSafety and Tolerance Evaluation of a Suncare Product in Ethnically Diverse Children With Atopic Dermatitis-Prone Skin
August 2024 | Volume 23 | Issue 8 | Original Article | 669 | Copyright © August 2024
Atopic dermatitis (AD) is a common chronic inflammatory skin condition, with high prevalence in children. Sun protection is important for children with eczema and AD-prone skin, yet many sunscree...
Read MoreImage Analysis of Xerosis and Atopic Dermatitis Following Prebiotic Skincare Regimen in Ethnically Diverse Patients
July 2024 | Volume 23 | Issue 7 | Original Article | 557 | Copyright © July 2024
Read MoreAnalysis of Reddit Reveals JAK Inhibitor Questions Among Atopic Dermatitis Patients
April 2024 | Volume 23 | Issue 4 | Editorials | e121 | Copyright © April 2024
Reddit is a popular social media website that is increasingly being used as a source of health information and discussion, especially among the younger population. We analyzed the subreddit "ecze...
Read MoreAttenuation of Atopic Dermatitis in Newborns, Infants, and Children With Prescription Treatment and Ceramide-Containing Skin Care: A Systematic Literature Review and Consensus
March 2024 | Volume 23 | Issue 3 | Original Article | 152 | Copyright © March 2024
Background: Atopic dermatitis (AD) typically starts in infancy and early childhood. The chronic skin disorder is associated with recurrent flares, pruritus, and genetic predispos...
Read MoreTargeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis
February 2024 | Volume 23 | Issue 2 | Original Article | 23 | Copyright © February 2024
Atopic dermatitis (AD) is a chronic relapsing–remitting disease with a multifactorial etiology involving epidermal barrier and immunologic dysfunction. Topical therapies form the mainstay o...
Read MoreAtopic Dermatitis as a Paradoxical Reaction to Secukinumab in a Patient With Plaque Psoriasis
February 2024 | Volume 23 | Issue 2 | Case Reports | 97 | Copyright © February 2024
Paradoxical reactions to biologic agents used in the treatment of psoriasis are rare but have been reported with tumor necrosis factor (TNF) blockers and, more recently, with interleukin (IL)-17A...
Read MoreSarecycline as a Potential Treatment for Steroid-Induced Rosacea/Perioral Dermatitis: A Case Report
February 2024 | Volume 23 | Issue 2 | Case Reports | e55 | Copyright © February 2024
Selection of Nemolizumab Clinical Dosage for Atopic Dermatitis
October 2023 | Volume 22 | Issue 10 | Original Article | 1017 | Copyright © October 2023
Nemolizumab is a monoclonal antibody directed against the interleukin-31 receptor A subunit, which is involved in the pathogenesis of pruritus and inflammation in atopic dermatitis (AD). Clinical tria...
Read MoreDo Atopic Dermatitis Patient-Reported Outcomes Correlate With Validated Investigator Global Assessment? Insights From TARGET-AD Registry
April 2023 | Volume 22 | Issue 4 | Original Article | 344 | Copyright © April 2023
Background: Research examining associations between the clinician-reported validated Investigator Global Assessment for AD (vIGA-AD) and patient-reported disease burden is sparse...
Read MoreBurden, Control, and Treatment of Moderate to Severe Atopic Dermatitis in 2021: A United States Patient Survey Study
February 2023 | Volume 22 | Issue 2 | Original Article | 119 | Copyright © February 2023
Background: Recent data on unmet needs in the treatment of moderate to severe atopic dermatitis (AD) in the US are not available.
Objective: To describe disease...
Read MoreA Qualitative Study on Dupilumab's Impact on Atopic Dermatitis Among Adolescent and Adult Patients
February 2023 | Volume 22 | Issue 2 | Original Article | 148 | Copyright © February 2023
Background: Atopic dermatitis (AD) is the most common inflammatory skin disease and dupilumab is US Food and Drug Administration-approved in both adult and pediatric AD patients.
Read MoreAtopic Dermatitis Polypharmacy and Out-Of-Pocket Healthcare Expenses
February 2023 | Volume 22 | Issue 2 | Original Article | 154 | Copyright © February 2023
Background: Atopic dermatitis (AD) out-of-pocket (OOP) expenses are substantial and impact household finances. Prescription polypharmacy and its association with OOP expenses in AD is...
Read MoreAn Up-to-Date Approach to the Management of Seborrheic Dermatitis
December 2022 | Volume 21 | Issue 12 | Features | 1373 | Copyright © December 2022
Seborrheic dermatitis (SD) is a chronic, relapsing, inflammatory dermatosis with ambiguous pathophysiology of overcolonization of Malassezia combined with predisposing factors including sebocyte activ...
Read MoreConcurrent Interstitial Granulomatous Dermatitis and TNF-α Antagonist-Induced Lupus Syndrome Secondary to Adalimumab for Crohn's Disease
November 2022 | Volume 21 | Issue 11 | Case Reports | 1256 | Copyright © November 2022
Tumor necrosis factor (TNF) antagonists have revolutionized management for various autoimmune and inflammatory conditions, including rheumatoid arthritis (RA), inflammatory bowel disease, hidradenitis...
Read MoreMeasuring and Improving Adherence to Crisaborole 2% Ointment in Patients With Atopic Dermatitis
October 2022 | Volume 21 | Issue 10 | Original Article | 1043 | Copyright © October 2022
Background: Atopic dermatitis (AD) is an inflammatory skin condition with dry, scaly, and intensely itchy skin. Treatment failure is the result of poor adherence.
Object...
Read More© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
